Cogent Biosciences, Inc.
COGT
株式のランク
#3368
Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted... Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST). Furthermore, Cogent holds a licensing pact with Plexxikon Inc., granting it rights for the investigation, advancement, and marketing of bezuclastinib. Previously known as Unum Therapeutics Inc., the company adopted its current name, Cogent Biosciences, Inc., in October 2020. Established in 2014, Cogent Biosciences is headquartered in Cambridge, Massachusetts.
株価
$30.04
時価総額
$5.21B
変化（1日）
1.76%
変化（1年）
83.28%
国
US
取引 Cogent Biosciences, Inc. (COGT)
カテゴリー
Healthcare
Cogent Biosciences, Inc.（COGT）のEPS
June 2026 時点のEPS TTM: $-2.31
Cogent Biosciences, Inc.の最新の財務報告と株価によると、同社の現在のEPS（TTM）は$-2.31です。2023年末には、EPSは$-2.42で、2022年のEPS$-2.26と増加でした。
Cogent Biosciences, Inc.のEPS履歴（2015から2026まで）
各年末時点のEPS
| 年 | EPS | 変化 |
|---|---|---|
| 2026 (TTM) | $-2.31 | -6.10% |
| 2024 | $-2.46 | 1.65% |
| 2023 | $-2.42 | 7.08% |
| 2022 | $-2.26 | 22.16% |
| 2021 | $-1.85 | -69.17% |
| 2020 | $-6.00 | 51.13% |
| 2019 | $-3.97 | -28.47% |
| 2018 | $-5.55 | 60.87% |
| 2017 | $-3.45 | 11.29% |
| 2016 | $-3.10 | 174.34% |
| 2015 | $-1.13 | 0.00% |
同様の企業または競合他社のEPS
| 企業 | EPS | EPSの差 | 国 |
|---|---|---|---|
| $17.32 | -849.78% |
US
|
|
| $-7.98 | 245.45% |
US
|
|
| $-5.29 | 129.00% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -1,300.87% |
NL
|
